Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
aluminum hydroxide (Gaviscon) (2 trials)
alvac-hiv vaccine (2 trials)
bacille calmette-guerin (1 trial)
bivalent subtype c gp120 (2 trials)
desflurane (suprane) (2 trials)
hiv-1 dna plasmid vaccine (1 trial)
mf59 (1 trial)
mrkad5 hiv-1 gag/pol/nef (2 trials)
mtbvac (1 trial)
recombinant adenoviral serotype 5 vector vaccine (1 trial)
trivalent mrkad5 hiv-1 gag/pol/nef (1 trial)
vcp1521 (2 trials)
vrchivadv014-00-vp (2 trials)
vrc-hivdna-016-00-vp (1 trial)
3m-052-af (2 trials)
ad26.enva.01 vaccine (1 trial)
ad35-env (1 trial)
adc6-hivgp140 (1 trial)
adc7-hivgp140 (1 trial)
aidsvax b/e (3 trials)
aluminum (1 trial)
avx101 (2 trials)
bg505 sosip.664 gp140 (1 trial)
ch505tf gp120 (2 trials)
cpg 1018 (1 trial)
dna-c2 (1 trial)
dna con-s env (2 trials)
dna-hiv-pt123 (3 trials)
dna mosaic env (2 trials)
dna nat-b env (2 trials)
ep-1233 (1 trial)
gla-lsq (1 trial)
gla-se (2 trials)
glycoprotein 140 (1 trial)
h4 (1 trial)
ic31 (1 trial)
il-12 dna (1 trial)
interleukin-12 (1 trial)
interleukin-15 (1 trial)
mva-c (1 trial)
mva-cmdr (1 trial)
mva-hiv62 (1 trial)
mva-mbn32 (1 trial)
nyvac-b (1 trial)
nyvac con-s env vaccine (1 trial)
nyvac-hiv-pt1 (2 trials)
nyvac-hiv-pt4 (2 trials)
nyvac mosaic env vaccine (1 trial)
nyvac nat-b env vaccine (1 trial)
pennvax-b (1 trial)
pga2/js7 (1 trial)
pgdm1400 (1 trial)
pgt121 (2 trials)
protein/mf59 (1 trial)
rad35 (1 trial)
rad5 (2 trials)
saavi dna-c2 vaccine (1 trial)
saavi mva-c vaccine (1 trial)
sd-np-gt8 (1 trial)
trimer 4571 (1 trial)
v520 (1 trial)
vir-1388 (1 trial)
vrc01.23ls (1 trial)
vrc07-523ls (1 trial)
vrc-hivadv027-00-vp (1 trial)
vrc-hivadv038-00-vp (1 trial)
vrc-hivdna009-00-vp (1 trial)
vrc-hivdna044-00-vp (1 trial)
Acquired Immunodeficiency Syndrome (Phase 2)
Adenoviridae Infections (Phase 1)
HIV Infections (Phase 2)
Infections (Phase 2)
Tuberculosis (Phase 1)
Vaccinia (Phase 1)
Trials (35 total)
Trial APIs (68 total)